Agilent Technologies Posts Higher Revenue, Operating Income, Net Income and Diluted EPS on Both Three-Month and Six-Month Windows in Interim Filing

Bottom line

- AGILENT TECHNOLOGIES, INC. filed its interim report under 10-Q for the period the three months ended April 30, 2026, with the accompanying year-to-date window the six months ended April 30, 2026, and the matching prior-year comparatives the three months ended April 30, 2025 and the six months ended April 30, 2025 also presented in the same statement set. The filing was made under accession 0001090872-26-000055 and identified by CIK 0001090872 and ticker A, covering the fiscal period period-ended-2026-04-30 referenced throughout the document.

- All four headline profitability measures in the statement of operations moved in the same authorized direction, year over year, on both reporting windows. 27 per diluted share per share respectively. Net Income (Loss) Attributable to Parent was higher on the three months ended April 30, 2026 than on the three months ended April 30, 2025 and higher on the six months ended April 30, 2026 than on the six months ended April 30, 2025, again profit to profit on both windows, at $339,000,000 and $644,000,000.

- Operating Income (Loss) tracked the same authorized pattern, higher year over year on both windows and remaining a profit rather than a loss. The quarter measure, at $399,000,000, exceeded the the three months ended April 30, 2025 comparative of $300,000,000, and the year-to-date measure of $752,000,000 exceeded the the six months ended April 30, 2025 comparative of $676,000,000. - Top-line Revenue from Contract with Customer, Excluding Assessed Tax also moved in the authorized direction.

The current quarter revenue of $1,835,000,000 was higher than the the three months ended April 30, 2025 comparative of $1,668,000,000, and the year-to-date revenue of $3,633,000,000 was higher than the the six months ended April 30, 2025 comparative of $3,349,000,000. The filing evidence does not attribute this change to any single cause. S.

GAAP, with the October comparative balance sheet data derived from audited statements; readers are referred to the Annual Report on Form noted in the introduction and to the Risk Factors discussion under Item 1A for forward-looking context, and to Item 4 for Controls and Procedures commentary. The disclosure environment also references the Supreme Court tariff ruling, the IEEPA refund portal launch, and pending geopolitical tensions in the Middle East, each flagged by management as something to monitor rather than as a quantified driver of the reported figures.

The filing evidence contains no peer or industry comparison.

Financial performance

YOY - Reported performance for the issuer covered by 10-Q period-ended-2026-04-30 under accession 0001090872-26-000055 frames both periods as profitable, and the headline revenue line, operating result, bottom-line net result and diluted earnings per share all shifted upward against the prior-year comparative on both the three-month and six-month year-to-date windows. - Revenue from Contract with Customer, Excluding Assessed Tax for the three-month period was higher than $1,668,000,000, and the six-month year-to-date figure came in higher than $3,349,000,000. - Operating Income (Loss) for the three-month period was higher than $300,000,000, and the six-month year-to-date operating result was higher than $676,000,000. - Net Income (Loss) Attributable to Parent for the three-month period was higher than $215,000,000, and the six-month year-to-date figure was higher than $533,000,000. - Earnings Per Share, Diluted for the three-month period was higher than $0.75 per diluted share, and the six-month year-to-date diluted figure was higher than $1.86 per diluted share. - The filing does not attribute these year-over-year movements to any single cause. The filing evidence does not attribute this change to any single cause.

QOQ - Sequentially, the same four lines all register higher on the more recent three-month window than on the prior-year three-month comparative: Revenue is higher than $1,668,000,000, Operating Income is higher than $300,000,000, Net Income is higher than $215,000,000, and Diluted EPS is higher than $0.75 per diluted share, each preserved in a profit-to-profit transition. - The cumulative six-month year-to-date line likewise comes in higher than $3,349,000,000 for revenue, higher than $676,000,000 for operating result, higher than $533,000,000 for net result, and higher than $1.86 per diluted share for diluted EPS. - No sequential (quarter-versus-prior-quarter) change is asserted because that prior-quarter comparative is not catalogued here; the only intra-year pairing available is quarter-versus-prior-year-quarter and half-year-versus-prior-year-half-year.

GUIDANCE EXPECTATIONS - The filing language describes the CBP online portal for IEEPA tariff refund requests, an in-progress Biocare acquisition expected to close no later than the end of the fiscal year referenced in period-ended-2026-04-30 and to be reported within the Life Sciences and Diagnostics Markets segment, and acknowledged geopolitical pressure in the Middle East. Management states the Middle East conflict did not have a material impact on results of operations through the second quarter, citing mitigation strategies developed in response to tariff pressures. None of these items is a quantified forward-period revenue or earnings guidance; the filing therefore does not publish formal guidance figures that can be tabled against the reported results. The filing evidence contains no peer or industry comparison.

Accounting context for the unaudited condensed consolidated statements draws on revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement benefit plan assumptions, and accounting for income taxes as critical accounting policies, with restricted cash combined with cash and cash equivalents on the statement of cash flows. Fair-value measurement relies on Level 1 inputs for long-term debt and internally estimated inputs tied to active markets for foreign-currency hedging contracts, with additional detail in Note 9 covering fair value of financial instruments. The consolidated equity discussion ties to Note 12 covering total equity and preferred-stock par-value disclosures. Readers comparing this issuer against peers can cross-reference the prior-year-on-year profit-to-profit pattern at REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in the reporting period Filing to test how widespread that same directional pattern is this cycle.

Operating drivers and segments

- The filing presents only consolidated revenue and operating income for AGILENT TECHNOLOGIES, INC. on the three-month and six-month windows; segment-level figures (for example, Life Sciences and Diagnostics Markets versus the other markets groups) are not surfaced in the quoted source narrative, so segment drivers cannot be itemised here. - Reported revenue for the three-month period the three months ended April 30, 2026 was $1,835,000,000 USD versus $1,668,000,000 USD in the three months ended April 30, 2025, an authorised increase from the prior year.

- Reported revenue for the six-month year-to-date period the six months ended April 30, 2026 was $3,633,000,000 USD versus $3,349,000,000 USD in the six months ended April 30, 2025, also an authorised increase. - Reported operating income for the three-month period the three months ended April 30, 2026 was $399,000,000 USD versus $300,000,000 USD in the three months ended April 30, 2025, a profit-to-profit increase. - Reported operating income for the six-month period the six months ended April 30, 2026 was $752,000,000 USD versus $676,000,000 USD in the six months ended April 30, 2025, a profit-to-profit increase.

- The BioCare acquisition is described in the quoted narrative as going into the Life Sciences and Diagnostics Markets segment from the date of close, which could change future segment composition, but no contribution is embedded in the current-quarter or year-to-date results because close is stated to occur later in the fiscal year. - Management attributes operational resilience during the quarter to mitigation strategies developed in response to ongoing tariff pressures, stating that the recent Middle East conflict did not have a material impact on results of operations through the second quarter.

S. Supreme Court invalidation of certain tariffs imposed under the International Emergency Economic Powers Act, notes that the company has submitted refund claims for eligible tariffs through the CBP portal, and flags the timing and approval of any refunds as uncertain and contingent on further legal, regulatory, and administrative developments; any refunds are to be accounted for under the gain contingency model. - Management acknowledges broader macro headwinds (global economic and financial market conditions, foreign currency fluctuations, and customer demand variability) and points readers to the Risk Factors discussion in Part II of 10-Q (Item 1A) for additional context.

- Management notes the recent escalation of geopolitical tensions in the Middle East and surrounding regions as a source of increased global economic uncertainty and potential inflationary pressure, while reiterating that the situation is rapidly changing and will be monitored. - On the BioCare deal, management flags legal and regulatory approvals and customary closing conditions, with closing potentially occurring in the third quarter or no later than the end of the fiscal year. - The filing is governed by US GAAP and was prepared in accordance with the rules and regulations of the SEC; management identifies critical accounting policies as revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement benefit plan assumptions, and accounting for income taxes.

- The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison.

Cash flow and capital

Reported facts in the condensed consolidated statement of cash flows and the related balance sheet caption lines are the spine of this section. Over the six-month year-to-date window, AGILENT TECHNOLOGIES, INC. continued to generate a positive operating cash inflow, while financing and investing activities each ran in a negative direction. The exact dollar magnitudes are catalog-sourced and are inserted by the machine after this draft is finalized. On the investing side, payments to acquire property, plant and equipment, which is the headline capital expenditure line, are disclosed both for the current half-year and for the prior-year comparative half-year; both amounts appear in the catalog as positive-direction outflows. Common stock repurchases are also reported as a positive-direction cash outflow across the same two comparative windows. Ordinary common stock dividends are reported on both a three-month and a six-month basis, with the prior-year comparative figures also disclosed.

Management explanation around these flows is limited inside the filing evidence. The filing discusses carrying-value versus fair-value methodology for several instruments and confirms that the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued compensation and other accrued liabilities approximate fair value because of their short maturities. That disclosure speaks to valuation mechanics rather than to the underlying drivers of the cash-flow movements, so the explanation for why each line moved year over year is not stated in the filing text. The disclosure does describe the fair-value treatment of equity holdings, the use of market-corroborated inputs for foreign-currency hedges, and the cross-reference to the cited fair-value note for additional detail. None of that language is positioned as a cause-and-effect narrative for the cash flow statement itself.

Analyst inference is therefore constrained. The cash-flow profile is consistent with a mature, cash-generative issuer that funds capital expenditures, returns cash to shareholders through both repurchases and dividends, and runs a net investing outflow alongside a net financing outflow on a year-to-date basis. That inference is qualitative only: the catalog does not expose share-count math, free cash flow derivation, payout ratio, or buyback-yield inputs, so the article cannot derive those ratios in its own words. The qualitative shape — operating cash positive, investing cash negative, financing cash negative — is the only structural observation the analyst layer can offer without inventing numbers.

Counter-evidence and unknowns are worth flagging. The filing evidence does not disclose a segment-level split for cash flow lines, so any inference about which end market drove the investing outflow cannot be drawn. The filing evidence does not disclose segment-level detail for this dimension. applies in that direction. The filing also does not provide a peer or industry cash-flow benchmark inside the quoted evidence, so comparative framing against similar issuers is not available. The filing evidence contains no peer or industry comparison. applies there. The cause-and-effect question — why financing and investing flows shifted year over year — is similarly unresolved in the quoted text; The filing evidence does not attribute this change to any single cause. is the appropriate machine-owned line for any reader question of that shape.

On the balance sheet side, two current-line captions carry the cash-and-working-capital story: cash and cash equivalents at carrying value, and accounts payable, current. Both are reported at the balance sheet date in the catalog and are not re-derived here. Accounts payable is reported as a positive-direction current liability, while cash is a positive-direction current asset. The narrative on the balance sheet is intentionally narrow because the cash-flow, balance sheet, and capital allocation section is scoped to those two caption lines plus the cash-flow statement.

Capital allocation can be read off three outflow lines: payments to acquire property, plant, and equipment (capital expenditure), payments for repurchase of common stock, and payments of ordinary dividends on common stock. The catalog carries each of these on both the current half-year and the prior-year half-year, with dividends additionally disclosed on a quarterly basis. reported comparisons establish that capital expenditures moved lower year over year, share repurchases moved lower year over year, and ordinary dividends moved higher year over year on both the quarterly and the six-month windows. These authorized directions are the only year-over-year movements the prose is permitted to assert, and they are reported without an explanatory cause.

A reader looking to compare this capital allocation shape with another recent filing can cross-reference the REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in the reporting period Filing insight for context on how a different issuer in the same reporting window presented its cash-flow and capital-return picture.

Peer and historical context

- Reported figures from the AGILENT TECHNOLOGIES, INC. 10-Q for period-ended-2026-04-30 under accession 0001090872-26-000055 are framed here strictly against the prior-year comparatives shown in the same statement; a like a peer cohort or index benchmark is not provided inside the filing, so any outside issuer comparison sits outside the filing evidence The filing evidence contains no peer or industry comparison.. - Revenue from Contract with Customer, Excluding Assessed Tax moved higher than the prior period on both reporting windows: the three-month result of $1,835,000,000 for the three months ended April 30, 2026 sits above the prior-year comparative of $1,668,000,000 for the three months ended April 30, 2025, and the six-month year-to-date result of $3,633,000,000 for the six months ended April 30, 2026 sits above the prior-year comparative of $3,349,000,000 for the six months ended April 30, 2025; the reported direction for each window is an increase, and the transition in each case is positive to positive.

- Operating Income (Loss) likewise stepped up on both windows: the three-month result of $399,000,000 for the three months ended April 30, 2026 is higher than $300,000,000 for the three months ended April 30, 2025, and the six-month year-to-date result of $752,000,000 for the six months ended April 30, 2026 is higher than $676,000,000 for the six months ended April 30, 2025; each comparison carries an authorized increase direction and a profit-to-profit transition. - Net Income (Loss) Attributable to Parent followed the same shape, with the three-month result of $339,000,000 for the three months ended April 30, 2026 above $215,000,000 for the three months ended April 30, 2025, and the six-month year-to-date result of $644,000,000 for the six months ended April 30, 2026 above $533,000,000 for the six months ended April 30, 2025; both transitions remain profit to profit on an authorized increase direction.

- The headline growth profile is therefore consistent across revenue, operating income and net income on the three-month window and on the six-month year-to-date window, with no break in sign between the two periods and no offsetting weakness on the year-to-date aggregate; readers comparing windows can see that the year-to-date result is higher than the prior year-to-date result on every dimension listed above. - Net Cash Provided by (Used in) Operating Activities, however, moved in the opposite direction: the six-month year-to-date result of $545,000,000 for the six months ended April 30, 2026 is lower than the prior-year comparative of $652,000,000 for the six months ended April 30, 2025 on an authorized decrease direction, while both periods remain positive; this is the only authorized comparison in the catalog that runs against the income-statement trend.

- The filing evidence does not attribute this change to any single cause. - Because the filing does not name peer issuers, segment-level moves inside revenue, or a like a single driver behind the cash-flow step-down, the cleanest read of the comparative evidence is that AGILENT TECHNOLOGIES, INC. posted a profit-to-profit increase on revenue, operating income and net income for both the three-month and six-month windows against the prior year, with operating cash flow lower than the prior year-to-date period on an authorized decrease direction The filing evidence contains no peer or industry comparison..

- Readers who want a recent benchmark for the same profit-to-profit pattern on both windows can weigh this filing against the REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing write-up, which carries a similar year-over-year increase on the same three dimensions; the comparison is offered only as a framing reference, not as a peer data point.

Scenario analysis

A base case reads the latest interim results as a continuation of the existing growth path. Revenue from Contract with Customer, Excluding Assessed Tax of $1,835,000,000 USD for the three months ended April 30, 2026 is higher than $1,668,000,000 USD for the three months ended April 30, 2025, and the year-to-date figure of $3,633,000,000 USD for the six months ended April 30, 2026 is higher than $3,349,000,000 USD for the six months ended April 30, 2025, matching the authorized direction of revenue growth on both windows.

Net Income (Loss) Attributable to Parent of $339,000,000 USD for the three months ended April 30, 2026 is higher than $215,000,000 USD for the three months ended April 30, 2025, and the six-month profit of $644,000,000 USD for the six months ended April 30, 2026 is higher than $533,000,000 USD for the six months ended April 30, 2025, matching the authorized profit-to-profit, higher-on-both-windows pattern. In a base scenario, performance simply carries forward, with no new disclosures in Item 1A or Item 4 materially altering the trajectory.

An upside case layers a positive read on the same authorized comparisons. The quarter's higher revenue of $1,835,000,000 USD versus $1,668,000,000 USD, paired with a higher quarter profit of $339,000,000 USD versus $215,000,000 USD, suggests momentum extending past the prior year on the shorter window. The year-to-date pair of $3,633,000,000 USD above $3,349,000,000 USD and $644,000,000 USD above $533,000,000 USD reinforces that read on the longer window.

The upside framing assumes the equity disclosures captured in Note 12 support continued execution, while fair-value disclosures linked to Note 9 and Level 1 remain orderly. The filing evidence does not attribute this change to any single cause.. A downside case still concedes higher year-over-year values, but reads the same authorized comparisons through a cautious lens.

The quarter moves from $215,000,000 USD to $339,000,000 USD and the half-year from $533,000,000 USD to $644,000,000 USD remain profit-to-profit transitions, but the magnitude could narrow if the cost base expands faster than top-line gains. , and the filing provides no peer benchmark, The filing evidence contains no peer or industry comparison.. The filing evidence does not attribute this change to any single cause..

Readers weighing a similar profit-to-profit setup can cross-check the pattern in Lizely Finance Earnings Analysis — ANI Pharmaceuticals Interim Filing, which reported the same authorized direction on both reporting windows.

Risks and what to watch

The forward-looking picture drawn from this filing carries several flags that readers should weigh before treating the latest results as a steady-state. The official text in the cited note outlines vesting mechanics, holding-period rules, and valuation assumptions for equity-based compensation, but it does not separate how those programs are currently expected to dilute earnings, nor does it disclose the specific assumptions used this period. Because the assumptions are only described generically, readers cannot independently judge whether compensation-related dilution will expand, hold flat, or compress against prior periods, which is a meaningful consideration for $339,000,000 and the half-year figure.

Reported facts - Revenue for the three months ended April 30, 2026 came in at $1,835,000,000 USD, and for the six months ended April 30, 2026 at $3,633,000,000 USD. - Revenue for the prior-year comparative windows was $1,668,000,000 USD for the three months ended April 30, 2025 and $3,349,000,000 USD for the six months ended April 30, 2025. - Net income for the three months ended April 30, 2026 was $339,000,000 USD, and for the six months ended April 30, 2026 was $644,000,000 USD. - Net income for the prior-year comparative windows was $215,000,000 USD for the three months ended April 30, 2025 and $533,000,000 USD for the six months ended April 30, 2025.

Management explanation - The cited note describes the framework around LTPP awards, restricted stock units, stock options, and the assumption methodology used to value those awards, with vesting and holding-period schedules applied to historical grants. - Discontinued programs, such as employee stock options effective in a prior fiscal year, are noted but not quantified.

Analyst inference - The filing shows top-line growth on both the three-month and six-month windows, and net income moving in the same direction, with no margin commentary disclosed in the filing evidence. - The relationship between the period’s reported figures and any segment mix, currency, or pricing dynamic cannot be reconstructed from the cited note alone.

Counter-evidence - No opposing filed document or footnote contradicts the revenue or net income figures as presented. - The cited note does not provide prior-period assumption values, so any claim that equity-compensation expense is accelerating or moderating cannot be supported by the filing evidence.

Unknowns - Period-specific fair-value assumptions, expected vesting outcomes, and the resulting dilutive share count: The filing evidence does not attribute this change to any single cause.. - Segment-level revenue and operating income detail for the diagnostics, life sciences, and applied markets groups: The filing evidence does not disclose segment-level detail for this dimension.. - Peer or industry benchmark revenue growth or margin levels for the same windows: The filing evidence contains no peer or industry comparison..

Metrics to watch next period - Sequential and year-over-year change in $1,835,000,000 and $3,633,000,000 to confirm whether the current-quarter growth rate is sustained. - Whether $339,000,000 continues to expand at the same pace, and the implied operating leverage from any change in revenue versus change in net income. - Disclosure updates within Item 3 on market-risk exposures, since currency sensitivity is not otherwise detailed here. - Any updated disclosure under Item 1A on risk factors, which is the natural place for forward-looking exposure language. - The treatment of equity-based compensation expense in the income statement and any updated grant assumptions disclosed in the cited note. Readers comparing interim filings can also look at REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing for a parallel two-window profit-to-profit structure, which keeps the comparison honest while distinct in sector.